Fimea promotes human health in Finland by monitoring the quality, safety and traceability of grafts of human origin, such as blood products, tissue and cell grafts and organ transplants. In addition, Fimea supervises biobanks that maintain collections of research samples. The supervision covers licensing procedures, maintenance of the registers of operators and regular inspection activities.
Fimea processes reports of adverse events and adverse reactions linked to grafts of human origin and issues permits for the medical use of human organs, tissues and cells.
.svg/ad0e4ea8-b5cd-e13d-7ccf-31a35861df11?t=1670410747943)